Test Batch Production to Begin on Friday, July 19, 2019
Following the Company’s September 4, 2018 announcement of plans to release a functional beverage infused with CBD, Koios has resumed development with test batch production set to begin tomorrow. The CBD cannabinoid will be added to Koios’ “Fit SodaTM” line of functional beverages, as a method of enhancing the beverage’s effects. The Company temporarily suspended its development of a CBD-enhanced functional beverage in Q4 of 2018, citing a management decision to focus on existing product lines and retailer relationships, as well as an uncertain landscape with respect to CBD’s legality and its public perception. Koios will continue its working relationship with Colorado -based Keef Brands , who will supply crystalized water-soluble CBD for the proposed beverage.
VANCOUVER , July 18, 2019 /CNW/ – Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that it has made several key developments with respect to its proposed line of functional beverages containing broad-spectrum hemp extract cannabidiol (“CBD”). In a press release dated September 4, 2018 , the Company announced its plans to release a functional beverage, which would be infused with CBD to enhance the beverage’s effects. Koios will leverage its existing relationship with Colorado -based Keef Brands in the development of this product, with Keef Brands to supply crystalized, water-soluble CBD which will be added to Koios’ existing Fit SodaTM line of functional beverages. Starting tomorrow, the Company and Keef Brands will produce several test batches of the proposed CBD beverage, with user trials to begin shortly afterward.
CBD is a cannabinoid produced in the cannabis plant, and it is regularly used to treat inflammation, pain, anxiety and epileptic seizures. CBD differs from the tetrahydrocannabinol (“THC”) cannabinoid, in that it is not psychoactive and it does not create the same sensations commonly desired by users of cannabis as a recreational drug. The addition of CBD to Koios’ proprietary stack of nutrients, amino acids, and electrolytes in its Fit SodaTM line of beverages is expected to improve the product’s effects. Pending completion of further testing, the Company also plans to integrate CBD into its eponymous KOIOS beverage lineup at a later date. When the proposed beverage is released, Fit SodaTM will be available both with and without CBD.
Koios had elected to defer the finalization of the proposed CBD beverage from its original target of October 2018 based on a decision to place the Company’s full focus on its existing KOIOS and Fit SodaTM beverage lineups. With overwhelming success of these two product lines being distributed through some of the world’s largest retailers, the Company’s management deemed it to be in Koios’ best interests to capitalize on this existing demand which generates the most volume, profit and opportunity. Moreover, the overall perception of CBD from legal and scientific perspectives had been unclear for some time, creating a suboptimal landscape for products containing CBD. As a result, Koios has taken a passive approach to the introduction of CBD to its beverages, both in anticipation of the overall CBD landscape improving, as well as for taking the time to observe any “growing pains” experienced by other manufacturers who have sought to incorporate CBD into their product offerings, from which Koios has gleaned insight for solidifying its CBD product strategy.